Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.
Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, a minor system update with no user-facing content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedGlossary visibility controls were added (Show glossary / Hide glossary) and the page revision updated to v3.4.0. Update-related fields were reorganized: Last Update Submitted that Met QC Criteria and Last Update Posted were added, while the previous labels Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), and No FEAR Act Data were removed or adjusted.SummaryDifference0.1%
- Check28 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. This appears to be a metadata/version update and does not alter study details, eligibility criteria, or locations.SummaryDifference0.0%
- Check56 days agoChange DetectedLocations section expanded with numerous new sites across the US and other countries, and several previously listed locations were removed. The page revision updated from v3.3.2 to v3.3.3.SummaryDifference2%
- Check78 days agoChange DetectedNew study sites in Chiba, Sapporo, and Ishikawa (with local institution IDs) were added and several centers were removed. Revision 3.3.2 and updated milestone dates (e.g., 2025-11-21, 2026-02-27, 2031-02-27) accompany these changes.SummaryDifference0.7%
- Check85 days agoChange DetectedRemoved the notice about government funding and NIH operating status from the page; this does not affect the study details, eligibility criteria, or results information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.